| Name | Title | Contact Details |
|---|
KCAS Bioanalytical Labs is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Criterium is a Saratoga Springs, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We launched Absolute Insight in 2016 to empower business users in the healthcare sector, where our clients have used it to alleviate the opioid crisis, curb waste in the healthcare system, and target fraudulent entities. As an industry agnostic platform, we`ve began to expand our service across other verticals, fulfilling our mission to become the global gateway for business users to leverage advanced analytics and artificial intelligence at scale. With a deep understanding of your company`s pain points and a platform that makes advanced analytics truly easy, your business users can create data-driven actionable insights and automated pipelines. As data continues to double every two years, this solution is necessary across all industries. Make your data your best asset, and empower your employees with computational resources and algorithms to free them up to pursue more creative work.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Mass Medical Svc is a Arlington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.